Genmab — December 2024
-
Tror godt at JNJ udnytter optionen, hvis erzo differentierer sig fra faspro. Der er usikkerhed til prisen de kan forlange for faspro efter patentudløb på dara. Men kommer det prispres ikke fra US m.v. så vil der ikke blive solgt meget erzo før faspros patent udløber.
-
Royalty på tec og tal er low single digit. Nærmere 4%. Tec og tal indeholder kun et molekyle fra Genmab.Det
er kun rybrevant der har high single digit, da begge molekyler kommer fra Genmab. -
Det er nu "a mid-single digit royalty"
-
"mid single digit"
-
small new University trial- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma https://clinicaltrials.gov/study/NCT06723457
-
Det tror jeg ikke: Under our agreement with Janssen, Genmab is eligible to receive milestones and receives royalties between 8% and 10% on net sales of RYBREVANT, a mid-single digit royalty on net sales of TECVAYLI, and a mid-single digit royalty on net sales of TALVEY, all of which are subject to a reduction of such royalty payment in countries and territories where there are no relevant patents (as defined in the agreement), among other reductions.
-
Sukkeralf, det er oplyst flere gange på konferencer etc. Derfor forskellen på royalty procent I forhold til Rybrevant.
-
"The unprecedented durability of response seen in these data reinforce the potential of epcoritamab to become a core therapy for the treatment of multiple B-cell malignancies to benefit more patients," said Dr. Judith Klimovsky https://ml-eu.globenewswire.com/Resource/Download/5d2ab26b-5092-40d5-85c9-b653ab612acd
-
same from AbbVie
"More first-line treatments for diffuse large B-cell lymphoma are needed, especially for patients with aggressive disease markers that may impact the efficacy of current standard first-line therapies," said Lorenzo Falchi, M.D., Lymphoma Specialist, Department of Medicine, Memorial Sloan Kettering Cancer Center. "The durable responses observed in the study suggest significant potential for this first-line epcoritamab-based combination." -
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new...
AbbVie News Center (news.abbvie.com)
-
Genmab har mandag offentliggjort positive langsigtede data fra to igangværende kliniske forsøg med antistoffet Epcoritamab til behandling af diffust storcellet B-celle lymfom.
Det fremgår af en meddelelse til fondsbørsen mandag aften.https://borsen.dk/nyheder/virksomheder/genmab-leverer-igen-lovende-data-fra-kraefthab?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
-
Tak for den skarpe analyse nohope
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind